Aubagio 欧盟 - 挪威文 - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomide - multippel sklerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Lifmior 欧盟 - 挪威文 - EMA (European Medicines Agency)

lifmior

pfizer europe ma eeig - etanercept - arthritis, psoriatic; spondylitis, ankylosing; psoriasis - immunsuppressive - revmatoid artritt;juvenil idiopatisk arthritispsoriatic leddgikt;aksial spondyloarthritis;plaque psoriasis;paediatric plakkpsoriasis.

Gastrogard 370 mg/ g 挪威 - 挪威文 - Statens legemiddelverk

gastrogard 370 mg/ g

boehringer ingelheim animal health nordics a/s - omeprazol - oralpasta - 370 mg/ g

Alitretinoin Orifarm 10 mg 挪威 - 挪威文 - Statens legemiddelverk

alitretinoin orifarm 10 mg

orifarm generics a/s - alitretinoin - kapsel, myk - 10 mg

Alitretinoin Orifarm 30 mg 挪威 - 挪威文 - Statens legemiddelverk

alitretinoin orifarm 30 mg

orifarm generics a/s - alitretinoin - kapsel, myk - 30 mg

Teriflunomide Mylan 欧盟 - 挪威文 - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multippel sklerose, relapsing-remitting - immunsuppressive - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord 欧盟 - 挪威文 - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multippel sklerose, relapsing-remitting - immunosuppressants, selektiv immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Buprefarm 10 mikrog/ time 挪威 - 挪威文 - Statens legemiddelverk

buprefarm 10 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 10 mikrog/ time

Buprefarm 5 mikrog/ time 挪威 - 挪威文 - Statens legemiddelverk

buprefarm 5 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 5 mikrog/ time

Buprefarm 20 mikrog/ time 挪威 - 挪威文 - Statens legemiddelverk

buprefarm 20 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 20 mikrog/ time